Hopstem Bioengineering Co., Ltd. was founded on January 2017 in Hangzhou, by neuroscientists and stem cell biologists from Johns Hopkins University. Hopstem has established world-leading iPSCs platform of neural differentiation and cell engineering. Hopstem has developed several critical patented technologies，as well as CMC platform for iPSC-derived cell therapy products. Hopstem has iPSC reprogramming patent, GMP iPSC line with global licensing rights, iPSC-derived cell product manufacturing and quality system, and a variety of cell therapy products and pipelines, targeting CNS diseases, optical diseases and tumor. Hopstem's first clinical product - neural progenitor cell hNPC01 targets neural injury diseases such as stroke and traumatic brain injury, has received China's IND approval and entered clinical trials. Hopstem is committed to translating the most cutting-edge technologies to provide global patients with safe, efficient and affordable cell therapy products.浙江霍德生物工程有限公司于2017年1月成立，是一家全球创新、专注于开发iPSC衍生通用型细胞治疗产品的生物技术公司。霍德生物在iPSC重编程、多能干细胞神经分化及多种细胞工程方面具有领先的全球专利及创新技术优势，建立了iPSC细胞产品CMC平台，全悬浮自动生产工艺和多种创新分析方法。霍德生物已建立可用于境内外授权及生产的GMP iPSC细胞株，并拥有多款（包括神经细胞、眼科细胞、胰岛细胞等）在研产品，其中首个人前脑神经前体细胞hNPC01的中国IND申请已获批并进入临床，是目前国际开发速度最快的同类iPSC细胞产品，可针对脑卒中、颅脑损伤后遗症等未被满足的临床需求。